2,567 Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG) Purchased by Western Financial Corp CA

Western Financial Corp CA bought a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 2,567 shares of the medical equipment provider’s stock, valued at approximately $1,261,000.

Several other hedge funds have also made changes to their positions in ISRG. Capital Research Global Investors purchased a new position in Intuitive Surgical during the first quarter worth about $374,390,000. Vanguard Group Inc. lifted its stake in Intuitive Surgical by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after acquiring an additional 493,126 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its holdings in Intuitive Surgical by 51.2% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock valued at $356,524,000 after acquiring an additional 302,382 shares during the period. Strategic Financial Concepts LLC increased its stake in Intuitive Surgical by 40,221.4% during the second quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider’s stock worth $1,184,000 after purchasing an additional 265,461 shares during the period. Finally, GQG Partners LLC acquired a new stake in shares of Intuitive Surgical during the first quarter worth about $99,523,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Trading Down 0.2 %

NASDAQ:ISRG traded down $1.16 on Monday, reaching $519.99. The stock had a trading volume of 819,671 shares, compared to its average volume of 1,475,334. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $523.34. The stock has a market cap of $184.44 billion, a P/E ratio of 94.07, a price-to-earnings-growth ratio of 5.40 and a beta of 1.39. The company has a 50-day moving average of $483.85 and a 200 day moving average of $438.56.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings data on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.24. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. Intuitive Surgical’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.18 EPS. On average, equities analysts predict that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Insider Buying and Selling

In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the completion of the transaction, the director now directly owns 12,275 shares of the company’s stock, valued at $5,441,507.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Intuitive Surgical news, EVP Robert Desantis sold 376 shares of the business’s stock in a transaction on Monday, July 29th. The shares were sold at an average price of $446.60, for a total transaction of $167,921.60. Following the completion of the sale, the executive vice president now owns 5,506 shares in the company, valued at $2,458,979.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Amal M. Johnson sold 2,943 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the completion of the transaction, the director now owns 12,275 shares in the company, valued at approximately $5,441,507.50. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 53,120 shares of company stock worth $25,528,753. Insiders own 0.90% of the company’s stock.

Wall Street Analysts Forecast Growth

ISRG has been the subject of several recent research reports. BTIG Research set a $535.00 price target on shares of Intuitive Surgical in a research report on Friday. Barclays upped their target price on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a report on Thursday, July 18th. Morgan Stanley boosted their price target on Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Citigroup raised their price target on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Finally, Leerink Partners raised their target price on shares of Intuitive Surgical from $489.00 to $502.00 in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $513.74.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.